Pharmaceutical

Novo to buy Catalent: the backlash begins

Novo Nordisk’s plans to buy Catalent has raised objections related to the risk of drug shortages, manufacturing standards, and antitrust violations.

Feb 10, 2024 - 18:00
Novo to buy Catalent: the backlash begins
Novo Nordisk’s plans to buy Catalent has raised objections related to the risk of drug shortages, manufacturing standards, and antitrust violations.
Read the original article

Tags:

Previous Article

Another recall: does Philips have a quality control problem?

Next Article

Pharma and biotech concerned about the stability of large CROs, survey finds

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

China’s NMPA grants EUA to CSPC Pharmaceutical’s Covid-19 vaccine

China’s NMPA grants EUA to CSPC Pharmaceutical’s Covid-...

Mar 23, 2023

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Me...

Jul 1, 2023

STAT+: Saudi VC loops Novo Nordisk, other biotech VCs into new longevity incubator

STAT+: Saudi VC loops Novo Nordisk, other biotech VCs i...

Nov 29, 2023